Advertisement
Surgery
Advanced searchSave search
American Association of Endocrine Surgeon| Volume 148, ISSUE 6, P1191-1197, December 2010

Impact of second primary malignancy on outcomes of differentiated thyroid carcinoma

DOI:https://doi.org/10.1016/j.surg.2010.09.022
Impact of second primary malignancy on outcomes of differentiated thyroid carcinoma
Previous ArticleDifferentiation of precursors into parathyroid-like cells for treatment of hypoparathyroidism
Next ArticleManagement of cervical nodal metastasis detected on I-131 scintigraphy after initial surgery of well-differentiated thyroid carcinoma

      Background

      There are few data on the degree to which thyroid cancer survivors are at risk of second primary malignancy (SPM). This study aimed at evaluating the risk of SPM in patients with differentiated thyroid carcinoma (DTC) and how the timing of SPM might affect the disease course.

      Methods

      Among 1,043 patients diagnosed with DTC between 1970 and 2008, 27 (2.6%) had synchronous SPM (ie, diagnosed within 6 months of DTC) and 71 (6.8%) had metachronous SPM (ie, diagnosed >6 months after DTC) in 10,419 person-years of follow-up. Standardized incidence ratios were estimated overall and for each SPM site.

      Results

      DTC survivors had a 39% greater risk of SPM (SIR = 1.39; 95% CI, 1.09–1.73) compared to the general population. Those with SPM had a worse overall survival than those without SPM (P < .001). The synchronous group had a worse DTC-specific survival (P = .002), whereas the metachronous group had a worse SPM-specific survival (P = .042). A lesser proportion in the metachronous group were able to receive curative treatment for SPM (32/71 vs 20/27; P = .013).

      Conclusion

      DTC survivors had an increased risk of SPM. The occurrence of SPM adversely affected the survival of DTC. The synchronous group tended to die from DTC, whereas the metachronous group from SPM. Heightened postoperative surveillance might improve survival.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

      1. Cancer incidence and mortality in Hong Kong 1983-2006. Hong Kong Cancer Registry, Hong Kong. Available: http://www3.ha.org.hk/cancereg/e_stat.asp. Accessed July 15, 2009.

        View in Article
        • Lang B.H.
        • Lo C.Y.
        • Chan W.F.
        • Lam K.Y.
        • Wan K.Y.
        Prognostic factors in papillary and follicular thyroid carcinoma: implications for cancer staging.
        Ann Surg Oncol. 2007; 14: 730-738
        View in Article
        • Rubino C.
        • de Vathaire F.
        • Dottorini M.E.
        • Hall P.
        • Schvartz C.
        • Couette J.E.
        • et al.
        Second primary malignancies in thyroid cancer patients.
        Br J Cancer. 2003; 89: 1638-1644
        View in Article
        • Brown A.P.
        • Chen J.
        • Hitchcock Y.J.
        • Szabo A.
        • Shrieve D.C.
        • Tward J.D.
        The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer.
        J Clin Endocrinol Metab. 2008; 93: 504-515
        View in Article
        • Sandeep T.C.
        • Strachan M.W.
        • Reynolds R.M.
        • Brewster D.H.
        • Scelo G.
        • Pukkala E.
        • et al.
        Second primary cancers in thyroid cancer patients: a multinational record linkage study.
        J Clin Endocrinol Metab. 2006; 91: 1819-1825
        View in Article
        • Wong I.O.
        • Chan W.S.
        • Choi S.
        • Lo S.V.
        • Leung G.M.
        • on behalf of the Health Care Financing Study Group
        Moral hazard or realised access to care? Empirical observation in Hong Kong.
        Health Policy. 2006; 75: 251-261
        View in Article
        • Canchola A.J.
        • Horn-Ross P.L.
        • Purdie D.M.
        Risk of second primary malignancies in women with papillary thyroid cancer.
        Am J Epidemiol. 2006; 15: 521-527
        View in Article
        • Subramanian S.
        • Goldstein D.P.
        • Parlea L.
        • Thabane L.
        • Ezzat S.
        • Ibrahim-Zada I.
        • et al.
        Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis.
        Thyroid. 2007; 17: 1277-1288
        View in Article
        • Sawka A.M.
        • Thabane L.
        • Parlea L.
        • Ibrahim-Zada I.
        • Tsang R.W.
        • Brierley J.D.
        • et al.
        Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis.
        Thyroid. 2009; 19: 451-457
        View in Article

      10. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214.

        View in Article
        • Sadetzki S.
        • Calderon-Margalit R.
        • Peretz C.
        • Novikov I.
        • Barchana M.
        • Papa M.Z.
        Second primary breast and thyroid cancers (Israel).
        Cancer Causes Control. 2003; 14: 367-375
        View in Article
        • Ronckers C.M.
        • McCarron P.
        • Ron E.
        Thyroid cancer and multiple primary tumors in the SEER cancer registries.
        Int J Cancer. 2005; 117: 281-288
        View in Article
        • Verkooijen R.B.
        • Smit J.W.
        • Romijn J.A.
        • Stokkel M.P.
        The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer.
        Eur J Endocrinol. 2006; 155: 801-806
        View in Article
        • Cybulski C.
        • Gorski B.
        • Huzarski T.
        • Masojc B.
        • Mierzejewski M.
        • Debniak T.
        • et al.
        CHEK2 is a multiorgan cancer susceptibility gene.
        Am J Hum Genet. 2004; 75: 1131-1135
        View in Article
        • Lo C.Y.
        • Chan W.F.
        • Lang B.H.
        • Lam K.Y.
        • Wan K.Y.
        Papillary microcarcinoma: is there any difference between clinically overt and occult tumors?.
        World J Surg. 2006; 30: 759-766
        View in Article
        • Are C.
        • Hsu J.F.
        • Ghossein R.A.
        • Schoder H.
        • Shah J.P.
        • Shaha A.R.
        Histological aggressiveness of fluorodeoxyglucose positron-emission tomogram (FDG-PET)-detected incidental thyroid carcinomas.
        Ann Surg Oncol. 2007; 14: 3210-3215
        View in Article

      Article info

      Publication history

      Accepted: September 16, 2010

      Identification

      DOI: https://doi.org/10.1016/j.surg.2010.09.022

      Copyright

      Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX